ArticleHuman vaccines & immunotherapeutics2025
Progress toward elimination mother-to-child transmission of HBV in Shandong Province, China: Coverage trend in hepatitis B vaccination and HBIG administration, 2017-2024.
Article in Human vaccines & immunotherapeutics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 1 synthesis or guideline pooled it.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
To evaluate progress toward MTCT elimination of HBV, we analyzed 8-y trends in hepatitis B vaccine (HepB) and hepatitis B immune globulin (HBIG) administration coverage rates in Shandong province, focusing on high-risk populations. Data were collected from a provincial system, Shandong Vaccination Information System. Information of maternal HBsAg+ neonates born in 2017-2024 were extracted. Administration coverage in four groups (A: general newborn, B: maternal HBsAg+ neonates, C: preterm neonates with HBsAg+ mother, and D: birthweight <2000 g (LBW2000) neonates with HBsAg+ mother) were calculated. Joinpoint models were used to analyze changing trends over time, calculating annual percentage change (APC). From 2017 to 2024, the maternal HBsAg+ rate dropped from 2.85% to 2.10% (APC = -0.10,
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.